Compelled to advance innovation for patients and the urology community, oral presentations highlight real-world effectiveness of and patient adherence to ERLEADA® (apalutamide), plus PSA response from Phase 3 TITAN and SPARTAN studies in patients with advanced prostate cancer
San Francisco, CA (UroToday.com) — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13.